May 26, 2022

Stock News in Focus: Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) stock observed trading -95.23% off 52-week high price. On the other end, the stock has been noted 46.92% away from low price over the last 52-weeks. The stock disclosed a move of -28.54% away from 50 day moving average and -77.97% away from 200 day moving average. Moving closer, we can see that shares have been trading -20.69% off 20-day moving average. It has market cap of $12.21M.

On March 12, 2020, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, declared the retirement of Professor John L. Gainer, Ph.D., the company’s chief science officer.  Dr. Gainer will continue to serve as both an advisor to the Company and as a member of the board of directors. In recognition of the advancement of the TSC technology into the clinic, the Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.

Professor Gainer is the inventor of the trans bipolar carotenoid family of molecules from which the Company’s lead compound Trans Sodium Crocetinate, or TSC, was derived. He co-founded Diffusion Pharmaceuticals in 2001 with David Kalergis, the company’s chairman and chief executive officer, serving on the board of directors.  He was named chief science officer in 2005 after his retirement as Professor Emeritus at the University of Virginia Department of Chemical Engineering, where he had served as a faculty member since 1966.

On behalf of everyone at Diffusion Pharmaceuticals, we want to wish Professor Gainer the best with his well-deserved retirement, said Mr. Kalergis. We are pleased that we will have the benefit of John’s wisdom as both an advisor to the Company and as a board member, while we search for a new Chief Medical Officer to advance his work to offer treatment to patients suffering from diseases associated with a lack of oxygen.

The USA based company Diffusion Pharmaceuticals Inc. moved with change of 6.16% to $0.31 with the total traded volume of 714070 shares in recent session versus to an average volume of 2.49M. The stock was observed in the 5 days activity at -22.38%. The one month performance of stock was -28.57%. DFFN’s shares are at -45.58% for the quarter and driving a -94.15% return over the course of the past year and is now at -32.71% since this point in 2018.  Right now the stock beta is -0.09. The average volatility for the week and month was at 15.63% and 12.76% respectively. There are 39.38M shares outstanding and 33.33M shares are floated in market.

Shawn Harris is a Master’s in Business Administration by education. After completing his post-graduation, Shawn jumped the journalism bandwagon as a freelance journalist. Soon after that he landed a job of reporter and has been climbing the news industry ladder ever since to reach the post of editor. As an avid day trader, Shawn is a master of technical analysis and writes tirelessly on how stocks are trading. He has extensive knowledge in technical analysis & news writing.